The Autoimmune Pathway Study
Currently Recruiting
8 Apr 2026
Up to $7,300
Brisbane, Australia
We are exploring a new investigational drug that may be used in future studies for conditions linked to B cell activity. B cells play an important role in the immune system, and in some autoimmune diseases, such as systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathies, they can become overactive and contribute to inflammation.
This Phase 1 study is being conducted in healthy adults to understand how the investigational drug behaves in the body and to assess its safety and tolerability. Early studies like this help researchers gather the essential information needed about the drug so it can be tested in people living with autoimmune conditions.
Autoimmune conditions can significantly affect daily life, and researchers are continually working to understand new ways they might be treated in the future.
By taking part in this early study, you’ll be contributing to research that may guide the next steps in developing treatments for B cell–mediated autoimmune diseases.
Join our clinical trial
This is a first-in-human (FIH) study, meaning it is the first time the potential treatment is being tested in people. The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee. It is not known whether the study drug may cause unexpected, serious, or life-threatening side effects. While these are considered unlikely, you will be carefully monitored throughout the study and provided with prompt treatment if any such effects occur.
Before joining, you’ll receive detailed information about the study, meet with a doctor, and have the chance to ask any questions.
What to expect?
- Particpation in a monitored clinical environment.
- Study visits scheduled
- Support from a professional medical team
- Reimbursement for your time and commitment
Trial details
Study duration
4 nights stay,
10 follow-up visits,
6 phone calls
Study medication
Administered as an intravenous (IV) infusion
Additional eligibility
- Weight between 60-95kg
- Non-smokers or smoking less than 5 cigarettes per week
- Prior smokers, must have a history of less than 20packs year history
Ethics
An independent ethics committee has approved this clinical trial.
Are you a match?
Age
18 - 55 years old
Remuneration
Up to $7,300 *with screening reimbursement. Please see T&Cs.
Gender
Male or Female
Commitment
4 nights, 10 clinic visits